Primary immunodeficiency diseases encompass a heterogeneous group of inherited disorders affecting humoral immunity (B cells, antibody production), cellular immunity (T cells), complement, phagocytes, and innate immunity.
Primary immunodeficiency diseases encompass a heterogeneous group of inherited disorders affecting humoral immunity (B cells, antibody production), cellular immunity (T cells), complement, phagocytes, and innate immunity. Stem-cell research investigates whether fetal stem cells and placental mesenchymal stem cells can regenerate lymphoid tissue, promote T-cell and B-cell development within thymic or splenic niches, enhance phagocytic function, and restore immunological tolerance. With 91 registered trials and 13 currently recruiting, the biological rationale targets immune reconstitution through direct progenitor support and paracrine enhancement of developmental microenvironments. Early clinical data suggest potential for improving T-cell counts and function, enhancing antibody responses, reducing infection burden, and improving outcomes in severe combined immunodeficiency and other forms.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €19,000–€24,000 (bookinghealth.com) |
| Main cell types studied | Fetal Stem Cells, MSCs from Amniotic Membrane |
| Approval status | Approved (blood/immune only) |
| Registered trials (ClinicalTrials.gov) | 91 · 13 recruiting now |
For the clinic's own description, see how Stem Plus describes its Primary Immunodeficiency programme ↗.
Primary immunodeficiency trials represent a substantial evidence base reflecting disease severity and unmet medical need. Thirteen actively recruiting trials indicate ongoing clinical momentum. Published studies document improvements in T-cell counts, restored T-cell proliferation and cytokine production, enhanced antibody responses to vaccination, and reduced infection frequency in responsive cohorts following stem-cell infusion. Several trials in severe combined immunodeficiency showed establishment of T-cell reconstitution permitting reduced dependence on antimicrobial prophylaxis. However, study heterogeneity — varying immunodeficiency types, disease severity, prior treatments — limits generalisation. Long-term immune stability beyond 24 months remains incompletely characterised. Hematopoietic stem-cell transplantation remains the gold standard for select immunodeficiencies; MSC role is emerging as complementary or supportive.
Depending on assessment, a Primary Immunodeficiency protocol may draw on:
Primary immunodeficiency stem-cell treatment costs typically range €4,000–8,000 per infusion, reflecting the complexity of immunological assessment and monitoring. Fetal stem cells, when used, incur higher sourcing and manufacturing costs than placental MSCs, potentially exceeding €8,000 per cycle. Repeat infusions are common; multi-cycle protocols may total €15,000–25,000. Extensive immunological testing — T-cell subset enumeration, T-cell proliferation assays, antibody titers, vaccine responses — adds €1,500–3,000 to each cycle. Hospital-based immunology programmes typically charge €4,500–7,000; private boutique immune-therapy centres may exceed €8,000. European centres (Germany, Spain, Italy, Austria) generally offer more structured pricing than boutique clinics.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Primary Immunodeficiency cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Primary Immunodeficiency.
Full Primary Immunodeficiency FAQ → · Primary Immunodeficiency cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita